Mar 13, 2023 / 06:00PM GMT
Jay Olson - Oppenheimer & Co. Inc., Research Division - Executive Director & Senior Analyst
Hello, everyone, and welcome to Oppenheimer's 33rd Annual Healthcare Conference. I'm Jay Olson, one of the biotech analysts at Oppenheimer. And it's a pleasure to introduce Amgen and an honor to have Arvind Sood, Head of IR here today with us. And Susan Sweeney also joining, Senior VP of Global Marketing Access and Capabilities. So thank you both so much for joining us here today. Really appreciate it. It's a pleasure to see you both.
Arvind Sood - Amgen Inc. - VP of IR
Thank you, Jay. Thanks for inviting us. If you'd like to, I can just make some brief opening comments, then I'll turn it back to you and then we can delve into addressing any questions that you or any of the investors might have.
Jay Olson - Oppenheimer & Co. Inc., Research Division - Executive Director & Senior Analyst
Thank you, Arvind.
Arvind Sood - Amgen Inc. - VP of IR
And Jay, perhaps I'll just
Amgen Inc at Oppenheimer Healthcare Conference (Virtual) Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot